• Cyclopharm granted maximum 5-year US patent extension for Technegas to 2031
• Provides uninterrupted US market exclusivity, ensuring clear runway for value creation
• FDA review highlights Technegas' strong clinical profile and leadership in lung ventilation imaging

Cyclopharm Limited (ASX: CYC) has announced that the United States Patent and Trademark Office (USPTO) has granted the maximum allowable patent term extension of five years covering the Technegas Kit (technetium Tc-99m labelled carbon) to 2031. This milestone follows a comprehensive review by both the USPTO and the U.S. Food and Drug Administration (FDA), which confirmed that the patent covering Technegas qualified for a term extension under 35 U.S.C. § 156. As a result, the original patent, previously set to expire in 2026, has now been extended to 2031. The five-year extension granted represents the maximum duration permitted under U.S. law. This patent extension provides uninterrupted United States market exclusivity for Technegas through to early 2031, underscoring a significant competitive advantage and ensuring a clear runway for value creation in the world's largest healthcare market. It allows Cyclopharm to fully realise the commercial and clinical potential of Technegas in the United States in both diagnosing Pulmonary Embolism and a growing number of indications Beyond PE without the risk of near-term generic or biosimilar competition. The FDA's thorough regulatory review and continued support during the patent extension process highlight the strong and differentiated clinical profile of Technegas, further reinforcing its position as the leading nuclear medicine agent for functional lung ventilation imaging.

Cyclopharm continues to actively invest in a broader range of initiatives to extend protection for the Technegas platform and pipeline well beyond 2031, including new patent filings, next-generation developments and complementary intellectual property initiatives designed to ensure Cyclopharm's continued leadership in pulmonary imaging and related respiratory technologies.